At the source.
Segregation and the right container matter at the source. Mistakes travel downstream, putting waste handlers at risk.
Back to After Hours
SYSTEMS DESIGN / MEDICAL WASTE
What care leaves behind
I mapped medical waste from its sources to its environmental consequences. My question shifted from better disposal to why the system creates so much waste.
- Role
- Systems research, mapping and design exploration.
- Collaboration
- Collaborators not recorded.
- Period
- Dates not recorded.
- Scope
- Medical-waste lifecycle, pharmaceutical waste and leverage points.
TL;DR / Overview
- Problem
- Improving disposal alone leaves the healthcare decisions that generate waste unexamined.
- Role
- I mapped the waste lifecycle and stakeholder relationships, then explored intervention points.
- Surfaces
- Waste-source taxonomy, lifecycle and feedback-loop diagrams, pharmaceutical stakeholder mapping and a comparison using Meadows’ leverage points.
- Reach
- Qualitative systems research spanning households, care providers, pharmacies and pharmaceutical companies.
- Result
- The maps moved the inquiry upstream to purchasing, prescribing and distribution, shaping questions for further research.
- Status
- Systems-design research, not an implemented intervention.
01 / THE QUESTION
Care has a footprint.
Where could I intervene?
“Do no harm” is a healthcare principle. Yet care creates waste and pollution. I approached that tension as a systems problem, not a better-bin brief.
Beyond hospitals, I mapped households, laboratories, pharmacies, pharmaceutical companies, emergency services, nursing homes and veterinary clinics.
Sharps, dressings, diagnostic samples, chemicals, pharmaceuticals, medical devices and radioactive waste cannot be handled as one stream.
The study’s background estimate was about 85% general waste and 15% hazardous waste. That framed the problem without making general waste consequence-free.
I wanted to understand the full lifecycle: what generates the waste, how it moves, what treatment changes, and what still reaches land, air or water.
These proportions are cited background context, not project measurements.
02 / FOLLOWING THE WASTE
A disposal route
is not an end point.
Following collection, storage, transport and treatment through to their destinations exposed the limits of an end-of-pipe solution.
Between handoffs.
Waste waits for processing and moves between sites. Storage, access and transport are part of the design problem, not invisible steps between disposal and treatment.
After treatment.
Decontamination changes the waste, but does not make its environmental consequences disappear. I traced treatment routes through to their eventual destinations.
The flow was not acting alone.
Policy and law set rules and incentives. Technology affects the available treatment methods. Funding, education and culture influence what people and institutions can actually do.
Feedback changed the question.
I explored how recovery, recycling and treatment might change the loop. These maps locate possible interventions, not quantified energy or pollution savings.
03 / A SMALLER PART OF THE SYSTEM
Before a medicine expires,
why was it bought?
I narrowed the inquiry to pharmaceutical waste, looking beyond expired-drug disposal to demand, prescribing, supply and accumulation.
Patients, doctors, hospitals, pharmacies and pharmaceutical companies each influence what is bought, prescribed, stocked and discarded. Those decisions are interconnected.
How could we reduce overbuying, hoarding and unused stock while preserving necessary care and emergency supplies?
This moved the work upstream. I considered need-based access to medicines, prescription practices, diagnostic processes and the materials used in everyday hospital administration.
Prescribing needed closer research with doctors and hospitals: which medicines are needed, why one is chosen, how often conditions occur and where alternatives fit.
Buy closer to need.
I explored timely access to medicines as an alternative to accumulating stock that expires. Emergency availability remains part of that question.
Reduce avoidable material use.
Diagnostics and paper-based triage offered ways to reduce material consumption through service changes.
Understand what drives prescribing.
Education, commercial influences and distribution policies all belong in the picture. I treated these as areas for further study, not a single behavioural fix.
04 / FINDING LEVERAGE
Change the feedback,
not just the container.
The maps helped me compare interventions at different depths: materials and treatment, information and feedback, policies and the purpose of the system itself.
I used Meadows’ leverage points to organise the possibilities. A longer shelf life or a new treatment method changes a thing in the system. Information, prescribing rules and distribution policies change how the system operates. A shift from treating sickness towards supporting wellness questions its larger goal.
What is made and used.
Drug shelf life, treatment methods and modular medical equipment offer concrete intervention points.
How decisions are made.
Feedback, education, hospital services and distribution policies influence the flow long before disposal.
What care is trying to do.
Preventing illness changes the demand on the whole system, rather than improving one downstream stage.
05 / WHAT THE MAP MADE CLEAR
A place to start.
Not a claim of impact.
The useful shift was upstream.
I began after materials became waste; I ended with purchasing, prescribing, service delivery and prevention.
Making relationships visible helped me choose a specific question, rather than expect one product to solve the system.
The next step needs evidence.
Next steps included shelf life, production and consumption, equipment reuse and recycling, prescribing and distribution policy, always alongside access to care.
This systems inquiry produced no deployed intervention or measured reduction in waste, cost or environmental harm.
OTHER QUESTIONS IN HEALTHCARE
